Physician profile
Deanna Tran
NPI 1427172584
$4,538.52
in general payments reported to CMS, 2019-2025
16 companies · $597 in 2025
The $597 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $663 · 2020: $1,077 · 2021: $634 · 2022: $537 · 2023: $407 · 2024: $623 · 2025: $597.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,627.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,627.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,924.22 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Amgen INC. | $288.49 | 2025 | Repatha |
| Pfizer INC. | $243.69 | 2019-2024 | |
| Glaxosmithkline, LLC. | $178.72 | 2019-2023 | Pediarix, Bexsero |
| Abbott Laboratories | $163.63 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Exact Sciences Corporation | $140.67 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Novo Nordisk INC | $129.56 | 2019-2025 | Ozempic, Rybelsus |
| Phadia US INC. | $116.82 | 2021-2024 | Immunocap |
| Boehringer Ingelheim Pharmaceuticals, INC. | $115.61 | 2020-2022 | |
| Lilly USA, LLC | $74.56 | 2023-2024 | Mounjaro |
| Merck Sharp & Dohme LLC | $71.09 | 2019-2022 | |
| Ultragenyx Pharmaceutical INC. | $23.64 | 2023 | Crysvita |
| Sanofi Pasteur INC. | $22.75 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.20 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $14.09 | 2024 | Zoryve |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cranial Technologies, INC | $12.78 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deanna Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.